Skip to main content
. Author manuscript; available in PMC: 2014 Dec 23.
Published in final edited form as: ACS Nano. 2013 Nov 20;7(12):10597–10611. doi: 10.1021/nn404719c

Figure 9. Enhanced in vivo distribution of anti-M6PR carriers functionalized in mice.

Figure 9

(A) Circulation of anti-M6PR/NSM carriers (50:50 surface-coverage ratio) compared to control anti-M6PR/IgG carriers after intravenous injection in mice. (B) Enhancement (Δ) in the biodistribution of NSM-functionalized carriers was determined as the ratio of the specificity index of anti-M6PR/NSM carriers over that of anti-M6PR/IgG carriers, calculated as described in the Methods section. Mean ± standard error of the mean.